# Netskope Inc: financial statements, quarterly

NTSK · Nasdaq · CIK 2063196 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/ntsk.md) · [Financials](/companies/ntsk/financials.md) · [Filings](/companies/ntsk/filings.md) · [Insiders](/companies/ntsk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ntsk/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-04-30) | period not labelled (2024-07-31) | period not labelled (2024-10-31) | period not labelled (2025-01-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2025 (2025-10-31) | Q4 FY2025 (2026-01-31) | Q1 FY2026 (2026-04-30) | Q2 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [139](/filings/0001193125-25-316190.md) | [148 d](/filings/0001193125-26-135011.md) | [158](/filings/0001193125-26-255732.md) | [171](/filings/0001193125-26-380428.md) | [184](/filings/0001193125-25-316190.md) | [196 d](/filings/0001193125-26-135011.md) | [202](/filings/0001193125-26-255732.md) | [221](/filings/0001193125-26-380428.md) |
| Cost of revenue | $m | not reported | not reported | [46.8](/filings/0001193125-25-316190.md) | [49.2 d](/filings/0001193125-26-135011.md) | [48.2](/filings/0001193125-26-255732.md) | [47.5](/filings/0001193125-26-380428.md) | [77.5](/filings/0001193125-25-316190.md) | [53.1 d](/filings/0001193125-26-135011.md) | [53.3](/filings/0001193125-26-255732.md) | [57.5](/filings/0001193125-26-380428.md) |
| Gross profit | $m | not reported | not reported | [91.8](/filings/0001193125-25-316190.md) | [99.3 d](/filings/0001193125-26-135011.md) | [110](/filings/0001193125-26-255732.md) | [123](/filings/0001193125-26-380428.md) | [107](/filings/0001193125-25-316190.md) | [143 d](/filings/0001193125-26-135011.md) | [148](/filings/0001193125-26-255732.md) | [163](/filings/0001193125-26-380428.md) |
| Research and development | $m | not reported | not reported | [62.4](/filings/0001193125-25-316190.md) | [61.4 d](/filings/0001193125-26-135011.md) | [67.9](/filings/0001193125-26-255732.md) | [72.9](/filings/0001193125-26-380428.md) | [263](/filings/0001193125-25-316190.md) | [106 d](/filings/0001193125-26-135011.md) | [106](/filings/0001193125-26-255732.md) | [102](/filings/0001193125-26-380428.md) |
| Operating income | $m | not reported | not reported | [(53.8)](/filings/0001193125-25-316190.md) | [(41.2) d](/filings/0001193125-26-135011.md) | [(45.4)](/filings/0001193125-26-255732.md) | [(46.0)](/filings/0001193125-26-380428.md) | [(447)](/filings/0001193125-25-316190.md) | [(114) d](/filings/0001193125-26-135011.md) | [(109)](/filings/0001193125-26-255732.md) | [(89.8)](/filings/0001193125-26-380428.md) |
| Income tax | $m | not reported | not reported | [(0.5)](/filings/0001193125-25-316190.md) | [1.1 d](/filings/0001193125-26-135011.md) | [2.5](/filings/0001193125-26-255732.md) | [2.5](/filings/0001193125-26-380428.md) | [3.1](/filings/0001193125-25-316190.md) | [3.3 d](/filings/0001193125-26-135011.md) | [3.1](/filings/0001193125-26-255732.md) | [3.1](/filings/0001193125-26-380428.md) |
| Net income | $m | [(95.2)](/filings/0001193125-25-316190.md) | [(112)](/filings/0001193125-25-316190.md) | [(70.7)](/filings/0001193125-25-316190.md) | [(77.0) d](/filings/0001193125-26-135011.md) | [(79.2)](/filings/0001193125-26-380428.md) | [(90.3)](/filings/0001193125-26-380428.md) | [(453)](/filings/0001193125-25-316190.md) | [(56.8) d](/filings/0001193125-26-135011.md) | [(116)](/filings/0001193125-26-380428.md) | [(111)](/filings/0001193125-26-380428.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.72)](/filings/0001193125-25-316190.md) | not reported | [(0.76)](/filings/0001193125-26-255732.md) | [(0.84)](/filings/0001193125-26-380428.md) | [(1.85)](/filings/0001193125-25-316190.md) | not reported | [(0.29)](/filings/0001193125-26-255732.md) | [(0.27)](/filings/0001193125-26-380428.md) |
| Basic EPS | $ per share | not reported | not reported | [(0.72)](/filings/0001193125-25-316190.md) | not reported | [(0.76)](/filings/0001193125-26-255732.md) | [(0.84)](/filings/0001193125-26-380428.md) | [(1.85)](/filings/0001193125-25-316190.md) | not reported | [(0.29)](/filings/0001193125-26-255732.md) | [(0.27)](/filings/0001193125-26-380428.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-01-31) | period not labelled (2024-01-31) | period not labelled (2024-04-30) | period not labelled (2024-07-31) | period not labelled (2024-10-31) | period not labelled (2025-01-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2025 (2025-10-31) | FY2025 (2026-01-31) | Q1 FY2026 (2026-04-30) | Q2 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | [166](/filings/0001193125-26-135011.md) | not reported | not reported | [985](/filings/0001193125-25-316190.md) | [433](/filings/0001193125-26-380428.md) | [206](/filings/0001193125-26-255732.md) | [221](/filings/0001193125-26-380428.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | [528](/filings/0001193125-26-135011.md) | not reported | not reported | [1,402](/filings/0001193125-25-316190.md) | [1,449](/filings/0001193125-26-380428.md) | [1,371](/filings/0001193125-26-255732.md) | [1,386](/filings/0001193125-26-380428.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | not reported | [859](/filings/0001193125-26-135011.md) | not reported | not reported | [1,715](/filings/0001193125-25-316190.md) | [1,772](/filings/0001193125-26-380428.md) | [1,691](/filings/0001193125-26-255732.md) | [1,712](/filings/0001193125-26-380428.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | [527](/filings/0001193125-26-135011.md) | not reported | not reported | [603](/filings/0001193125-25-316190.md) | [682](/filings/0001193125-26-380428.md) | [632](/filings/0001193125-26-255732.md) | [689](/filings/0001193125-26-380428.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [1,344](/filings/0001193125-26-135011.md) | not reported | not reported | [1,564](/filings/0001193125-25-316190.md) | [1,578](/filings/0001193125-26-380428.md) | [1,515](/filings/0001193125-26-255732.md) | [1,555](/filings/0001193125-26-380428.md) |
| Shareholders' equity | $m | [27.8](/filings/0001193125-26-135011.md) | [(257)](/filings/0001193125-26-135011.md) | [(332)](/filings/0001193125-25-316190.md) | [(418)](/filings/0001193125-25-316190.md) | [(443)](/filings/0001193125-25-316190.md) | [(486)](/filings/0001193125-26-380428.md) | [(526)](/filings/0001193125-26-380428.md) | [(612)](/filings/0001193125-26-380428.md) | [151](/filings/0001193125-25-316190.md) | [195](/filings/0001193125-26-380428.md) | [176](/filings/0001193125-26-380428.md) | [157](/filings/0001193125-26-380428.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-01-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2025 (2025-10-31) | Q4 FY2025 (2026-01-31) | Q1 FY2026 (2026-04-30) | Q2 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [6.1 d](/filings/0001193125-26-135011.md) | [25.6](/filings/0001193125-26-255732.md) | [(16.9) d](/filings/0001193125-26-380428.md) | [11.2 d](/filings/0001193125-25-316190.md) | [18.1 d](/filings/0001193125-26-135011.md) | [(53.9)](/filings/0001193125-26-255732.md) | [(16.5) d](/filings/0001193125-26-380428.md) |
| Capital expenditure | $m | [1.3 d](/filings/0001193125-26-135011.md) | [7.4](/filings/0001193125-26-255732.md) | [1.6 d](/filings/0001193125-26-380428.md) | [0.5 d](/filings/0001193125-25-316190.md) | [13.4 d](/filings/0001193125-26-135011.md) | [2.2](/filings/0001193125-26-255732.md) | [13.0 d](/filings/0001193125-26-380428.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-10-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2025 (2025-10-31) | Q1 FY2026 (2026-04-30) | Q2 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [98.3](/filings/0001193125-25-316190.md) | [105](/filings/0001193125-26-255732.md) | [108](/filings/0001193125-26-380428.md) | [245](/filings/0001193125-25-316190.md) | [400](/filings/0001193125-26-255732.md) | [405](/filings/0001193125-26-380428.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.